PathDrugomics
PathDrugomics exponentially increases the efficiency of drug discovery and disrupts the billion dollar per compound cost of bringing a new therapeutic into the market. Our products utilize the speed of accelerating computational technologies and the intelligence of big data analytics to model interactions between newly discovered drugs and their possible targets within diseases.
PathDrugomics
PathDrugomics exponentially increases the efficiency of drug discovery and disrupts the billion dollar per compound cost of bringing a new therapeutic into the market. Our products utilize the speed of accelerating computational technologies and the intelligence of big data analytics to model interactions between newly discovered drugs and their possible targets within diseases.
TL;DR
Founded: 2012
Headquarters: San Francisco, California
Focus: Computational/AI-driven drug discovery and drug–target interaction modeling
Last known funding: Seed, July 2013 (~$30k)
Founders / CEO: Todd Meyerrose; Morio Alexander
Company Overview
Problem Domain
Drug discovery inefficiency and high per-compound development cost
Founded
2012
Industry
Biotechnology / Therapeutics
Funding Track Record
$30,000.00
Investor Signal
“Alchemist Accelerator participated in Seed round”